In eastern and western Uganda, 3,280 people will be followed for four years to track how chronic gut and liver conditions accumulate and interact after repeated rounds of deworming treatment. Intestinal schistosomiasis, caused by parasitic blood flukes, damages the gut and liver over years. Mass drug administration with praziquantel kills the parasites but does not reverse existing organ damage. The researchers recently found that even after repeated treatment, many people in Uganda still carry a high burden of conditions such as gut inflammation, liver scarring, enlarged spleen, and anaemia. The conventional view treats schistosomiasis as a single disease, but the team argues it is better understood as a set of multimorbidities—multiple chronic conditions that cluster within the same person. No one has systematically mapped how these conditions interact or what social and environmental factors drive their clustering. If the research succeeds, it could change how schistosomiasis programmes are designed. Instead of relying solely on mass drug administration to prevent morbidity, health systems might shift toward integrated management of chronic gut and liver conditions. The computational tools developed could help predict which individuals are most likely to develop severe complications, allowing earlier intervention. This is applied epidemiology with direct relevance to public health policy in sub-Saharan Africa.
View original technical description
Intestinal schistosomiasis is characterised by progressive injury to the gut and liver and caused by an infection of long duration with parasitic blood flukes (Schistosoma mansoni). Most infected individuals live in sub-Saharan Africa. Associated conditions include gut inflammation, hepatosplenomegaly, periportal fibrosis, portal hypertension, upper gastrointestinal bleeding, ascites, anaemia, and undernutrition. Mass drug administration (MDA) of praziquantel is used to treat the blood flukes instead of the conditions, relying on reaching individuals before morbidity develops. As a group of chronic conditions with complex aetiologies, we propose studying intestinal schistosomiasis as a set of multimorbidities as opposed to the conventional view as a single disease. Multimorbidity is the coexistence of 2+ chronic conditions within an individual irrespective of cause. It is rising worldwide and complicating diagnosis and case management. In Uganda, we recently discovered a high burden of gut and liver conditions despite repeated MDA. To establish the epidemiology of multimorbidities, we propose the following hypothesis. In the context of MDA, the accumulation and clustering of chronic S. mansoni-associated conditions within an individual, even in the short term (few years), is largely explained by interactions of those coexisting conditions and shared social-ecological risk factors between conditions within individuals. In Eastern and Western Uganda, we will establish a longitudinal, community-based cohort of 3,280 individuals for four years with six study periods. With major fieldwork, clinical and social epidemiology, and cutting-edge machine learning, our objectives are to 1) identify common clusters and interactions of gut and liver conditions; 2) develop computational tools to predict social-ecological patterning and condition trajectories; and 3) assess multimorbidities using patient-reported symptoms and priorities, and local health worker knowledge.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know